FDA Approves New Tx for Bladder Cancer – Zusduri
The FDA recently approved a new therapy, Zusduri (mitomycin) from UroGen Pharma. Zusduri, an alkylating drug, is indicated for the treatment of adult patients with
October 23, 2025
The FDA recently approved a new therapy, Zusduri (mitomycin) from UroGen Pharma. Zusduri, an alkylating drug, is indicated for the treatment of adult patients with
The FDA recently approved a new oral therapy, Zegfrovy (sunvozertinib) from Dizal (Jiangsu) Pharmaceutical Co., Ltd., for the treatment of adult patients with locally advanced
The 2025 JD Power US Pharmacy Study reveals significant shifts in pharmacy customer satisfaction and industry trends that pose major concerns for brick-and-mortar pharmacies. An
The FDA recently approved an ORAL therapy, Ekterly (sebetralstat) from KalVista Pharmaceuticals, indicated as an oral treatment for acute hereditary angioedema (HAE) attacks in patients
The latest round of price negotiations has captured the attention of industry insiders and consumers alike, signaling potential shifts across the market landscape. As companies
This Report takes a deep dive into the complex world of rare and orphan drugs – and the unique challenges of how they’re priced. This
The FDA recently approved a new infused therapy, Datroway (detumomab deruxtecan-dlnk) from AstraZeneca, indicated for the treatment of adult patients with unresectable or metastatic, hormone
The FDA recently approved a sub-q therapy, Yeztugo (lenacapavir) from Gilead, indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in
The FDA recently approved Andembry (garadacimab-gxii) from CSL for the prophylactic treatment of hereditary angioedema (HAE). This approval marks a significant milestone as Garadacimab is
Are you familiar with the term “Virtual Patients”? As the field of CGT (cell and gene therapy) rapidly evolves, understanding this concept will be increasingly